First UK participant enrolled into Pfizer’s Duchenne muscular dystrophy gene therapy trial.

Published Date
Research Team
Orange box stating: Breaking news research

In February we told you that the first gene therapy trial for Duchenne muscular dystrophy (DMD) was to start recruiting patients in the UK. You can read the story here. We are pleased to be able to share that the first participant has now been enrolled.

Pfizer’s ongoing clinical trial is testing the efficacy and safety of the potential gene therapy drug PF-06939926. The dosing of boys in the UK marks another exciting step for the DMD community.

Read Pfizer’s press release for more information.

Further information about the Pfizer DMD gene therapy trial, including eligibility, inclusion and exclusion criteria, can be found here. MDUK’s clinical trial FAQs can be accessed here.

If you have any research questions, please contact our Research Line on

Keep in touch